Cyberattack on the European Medicines Agency

EMA has been the subject of a cyberattack. The Agency has swiftly launched a full investigation, in close cooperation with law enforcement and other relevant entities.

EMA cannot provide additional details whilst the investigation is ongoing. Further information will be made available in due course.

Original source European Medicines Agency

Clinical Research News

Considerations for the Use of Real-World Data and Real-World Evidence To Support Regulatory Decision-Making for Drug and Biological Products
Submission of comments on ICH E6 (R3) Guideline for Good Clinical Practice(GCP) - Step 2b 
ICH E6(R3) Good Clinical Practice guidance - Step 2 Public Consultation
The study of the new investigational drug for acute myeloid leukemia and myelodysplastic syndrome
Open Label study of entrectinib in ROS1 gene fusion-positive rare adult, paediatric and teenage/young adult cancers
Gasherbrum Bio, Inc is starting the study of GSBR-1290 drug in overweight or obese healthy adults
A new study of Dexpramipexole in adolescents and adults with severe Eosinophilic Asthma

Upcoming Clinical Trials

Cyberattack on the European Medicines Agency

All jobs

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe